The tweet was deleted by the author.
But we saved everything 🙂.
Spyre Therapeutics, Inc. recently brought its team together for an annual in-person event, where employees assembled 1,500 kits for local students as part of the company's Women's History Month initiative.
The gathering also featured a physician panel with inflammatory bowel disease (IBD) specialists, reinforcing the company's commitment to community involvement and advancing medical understanding in its field.
View post on X Loading...
The company recently completed patient recruitment for the rheumatoid arthritis sub-study of its Phase 2 SKYWAY trial, with topline results expected in the third quarter of 2026, according to a previous update. Spyre Therapeutics continues to advance clinical efforts alongside its community initiatives. The trial progress follows a series of corporate milestones in its therapeutic pipeline.